vs
ACME UNITED CORP（ACU）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
ACME UNITED CORP的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.5倍（$52.3M vs $35.5M），ACME UNITED CORP净利率更高（1.9% vs -304.2%，领先306.1%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 13.8%），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs -2.9%）
埃克米联合公司（Acme United Corporation）是面向校园、家居、办公、五金及工业领域的切削工具、测量工具与安全防护用品供应商，行业历史悠久，其前身可追溯至1867年成立的合伙企业，1873年在康涅狄格州完成法人注册，目前在美国纽约泛欧美交所挂牌上市，股票代码为ACU。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
ACU vs RXRX — 直观对比
营收规模更大
ACU
是对方的1.5倍
$35.5M
营收增速更快
RXRX
高出667.9%
13.8%
净利率更高
ACU
高出306.1%
-304.2%
两年增速更快
RXRX
近两年复合增速
-2.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $52.3M | $35.5M |
| 净利润 | $985.0K | $-108.1M |
| 毛利率 | 39.7% | 59.8% |
| 营业利润率 | 3.3% | -304.8% |
| 净利率 | 1.9% | -304.2% |
| 营收同比 | 13.8% | 681.7% |
| 净利润同比 | -40.4% | 39.6% |
| 每股收益（稀释后） | $0.24 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACURXRX
| Q1 26 | $52.3M | — | ||
| Q4 25 | $47.5M | $35.5M | ||
| Q3 25 | $49.1M | $5.2M | ||
| Q2 25 | $54.0M | $19.2M | ||
| Q1 25 | $46.0M | $14.7M | ||
| Q4 24 | $45.9M | $4.5M | ||
| Q3 24 | $48.2M | $26.1M | ||
| Q2 24 | $55.4M | $14.4M |
净利润ACURXRX
| Q1 26 | $985.0K | — | ||
| Q4 25 | $1.9M | $-108.1M | ||
| Q3 25 | $1.9M | $-162.3M | ||
| Q2 25 | $4.8M | $-171.9M | ||
| Q1 25 | $1.7M | $-202.5M | ||
| Q4 24 | $1.7M | $-178.9M | ||
| Q3 24 | $2.2M | $-95.8M | ||
| Q2 24 | $4.5M | $-97.5M |
毛利率ACURXRX
| Q1 26 | 39.7% | — | ||
| Q4 25 | 38.2% | 59.8% | ||
| Q3 25 | 39.1% | -183.8% | ||
| Q2 25 | 41.0% | -4.9% | ||
| Q1 25 | 39.0% | -48.0% | ||
| Q4 24 | 38.7% | -181.4% | ||
| Q3 24 | 38.5% | 53.7% | ||
| Q2 24 | 40.8% | 36.2% |
营业利润率ACURXRX
| Q1 26 | 3.3% | — | ||
| Q4 25 | 6.1% | -304.8% | ||
| Q3 25 | 6.1% | -3327.6% | ||
| Q2 25 | 11.8% | -916.8% | ||
| Q1 25 | 5.3% | -1297.9% | ||
| Q4 24 | 5.0% | -4042.4% | ||
| Q3 24 | 6.1% | -377.1% | ||
| Q2 24 | 11.5% | -697.4% |
净利率ACURXRX
| Q1 26 | 1.9% | — | ||
| Q4 25 | 3.9% | -304.2% | ||
| Q3 25 | 3.9% | -3135.3% | ||
| Q2 25 | 8.8% | -894.2% | ||
| Q1 25 | 3.6% | -1373.3% | ||
| Q4 24 | 3.7% | -3935.5% | ||
| Q3 24 | 4.6% | -367.5% | ||
| Q2 24 | 8.0% | -676.6% |
每股收益（稀释后）ACURXRX
| Q1 26 | $0.24 | — | ||
| Q4 25 | $0.46 | $-0.17 | ||
| Q3 25 | $0.46 | $-0.36 | ||
| Q2 25 | $1.16 | $-0.41 | ||
| Q1 25 | $0.41 | $-0.50 | ||
| Q4 24 | $0.43 | $-0.56 | ||
| Q3 24 | $0.54 | $-0.34 | ||
| Q2 24 | $1.09 | $-0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.2M | $743.3M |
| 总债务越低越好 | $33.0M | $9.6M |
| 股东权益账面价值 | $116.7M | $1.1B |
| 总资产 | $195.2M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.28× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资ACURXRX
| Q1 26 | $4.2M | — | ||
| Q4 25 | $3.6M | $743.3M | ||
| Q3 25 | $5.1M | $659.8M | ||
| Q2 25 | $3.6M | $525.1M | ||
| Q1 25 | $3.4M | $500.5M | ||
| Q4 24 | $6.4M | $594.4M | ||
| Q3 24 | $5.7M | $427.6M | ||
| Q2 24 | $3.8M | $474.3M |
总债务ACURXRX
| Q1 26 | $33.0M | — | ||
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M |
股东权益ACURXRX
| Q1 26 | $116.7M | — | ||
| Q4 25 | $117.6M | $1.1B | ||
| Q3 25 | $115.8M | $1.0B | ||
| Q2 25 | $113.7M | $919.1M | ||
| Q1 25 | $108.3M | $933.9M | ||
| Q4 24 | $107.0M | $1.0B | ||
| Q3 24 | $106.3M | $524.6M | ||
| Q2 24 | $104.0M | $584.4M |
总资产ACURXRX
| Q1 26 | $195.2M | — | ||
| Q4 25 | $171.0M | $1.5B | ||
| Q3 25 | $173.0M | $1.4B | ||
| Q2 25 | $170.9M | $1.3B | ||
| Q1 25 | $163.0M | $1.3B | ||
| Q4 24 | $162.2M | $1.4B | ||
| Q3 24 | $165.5M | $726.5M | ||
| Q2 24 | $173.5M | $775.9M |
负债/权益比ACURXRX
| Q1 26 | 0.28× | — | ||
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流ACURXRX
| Q1 26 | — | — | ||
| Q4 25 | $8.2M | $-46.1M | ||
| Q3 25 | $7.1M | $-117.4M | ||
| Q2 25 | $6.3M | $-76.4M | ||
| Q1 25 | $-3.3M | $-132.0M | ||
| Q4 24 | $6.4M | $-115.4M | ||
| Q3 24 | $8.9M | $-59.2M | ||
| Q2 24 | $6.9M | $-82.2M |
自由现金流ACURXRX
| Q1 26 | — | — | ||
| Q4 25 | $7.3M | $-47.3M | ||
| Q3 25 | $301.0K | $-117.6M | ||
| Q2 25 | $4.7M | $-79.6M | ||
| Q1 25 | $-4.7M | $-133.8M | ||
| Q4 24 | $4.7M | $-116.7M | ||
| Q3 24 | $7.5M | $-63.8M | ||
| Q2 24 | $4.4M | $-83.4M |
自由现金流率ACURXRX
| Q1 26 | — | — | ||
| Q4 25 | 15.3% | -133.1% | ||
| Q3 25 | 0.6% | -2272.5% | ||
| Q2 25 | 8.7% | -413.9% | ||
| Q1 25 | -10.2% | -907.4% | ||
| Q4 24 | 10.2% | -2567.7% | ||
| Q3 24 | 15.6% | -244.6% | ||
| Q2 24 | 8.0% | -578.5% |
资本支出强度ACURXRX
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 3.5% | ||
| Q3 25 | 13.8% | 4.7% | ||
| Q2 25 | 3.0% | 16.4% | ||
| Q1 25 | 2.9% | 12.4% | ||
| Q4 24 | 3.7% | 28.6% | ||
| Q3 24 | 2.8% | 17.5% | ||
| Q2 24 | 4.5% | 8.2% |
现金转化率ACURXRX
| Q1 26 | — | — | ||
| Q4 25 | 4.34× | — | ||
| Q3 25 | 3.72× | — | ||
| Q2 25 | 1.33× | — | ||
| Q1 25 | -2.02× | — | ||
| Q4 24 | 3.73× | — | ||
| Q3 24 | 3.99× | — | ||
| Q2 24 | 1.55× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
